The company's lead drug candidate is a cannabis-derived canine pain medication.
Showing 25 of 1049
The SPP demonstrates that the company is willing to reward loyal shareholders.
The company has multiple medical cannabis research partners across the world.
The company’s shares are trading 28% higher intra-day, at 3.2 cents.
The heart valve device could be a game-changer in the US$3.5 billion market.
The company's shares are trading about 6% higher intra-day, at 46 cents.
The company now has complete end-to-end growing and manufacturing facilities.
According to the World Health Organisation, cardiovascular disease causes more than half of all deaths across Europe.
The companies intend to develop and produce CBD-based and THC-based products.
Medlab has approval to supply NanaBis™ under the TGA's Special Access Scheme.
Newly established relationship in Canda provides THC with access to additional cannabis strains.
An $8 million share purchase plan (SPP) will follow the placement.
The company has entered into a research services agreement Eurofins Animal Health Pty Ltd.
Negotiations between the parties involved have progressed well.
Current and former directors recently invested $700,000 in the company.
A new agreement will see the companies share medicinal cannabis product and knowledge.
The company has entered a research agreement which includes funding under the Kick-Start initiative for SMEs.
The company's shares are trading about 4% higher intra-day, at 24 cents.
Katy Williams Day is the new product and regulatory affairs manager for THC Pharma.
Approved Australian patients will be able to access products under the government’s Special Access Scheme.
The company has appointed Canadian Luke Pigeau and entered a research and development agreement with Jade Cannabis.
Rhinomed is a medical technology company with a patented nasal technology platform.
CannPal has identified an opportunity in the medical cannabis and health markets.
These patients are being treated by their doctors under the TGA Special Access Scheme.
Final stages of phase I studies and phase II enabling toxicity studies are due to complete in Q3 2018.